Analysis: Sanjiv.Parant.

What does Sanjiv.Parant. do?

• Sanjivani Paranteral Limited is a WHO GMP-certified pharmaceutical manufacturer with over 25 years of experience in sterile injectables, IV fluids, and oral solids.
• Headquartered in Mumbai, the company operates manufacturing facilities in Navi Mumbai and Dehradun, with strategic ventures in Pune (IV fluids) and Prague (nutraceuticals).
• FY25 marked a pivotal transition to a multi-vertical growth model through SPL Infusion Pvt. Ltd. (IV fluids) and Alevia Healthcare S.R.O. (nutraceuticals).

• Core business: Sterile injectables, oral solids, and bulk drugs, with exports to 25+ countries.
• Pune IV fluids facility (SPL Infusion Pvt. Ltd.) launched in FY25, targeting India and global markets.
• Prague-based nutraceutical venture (Alevia Healthcare S.R.O.) entered European markets in FY25.

Growth thesis

Sanjivani Parant. is a WHO-GMP certified pharma manufacturer specializing in sterile injectables, IV fluids, and oral solids, exporting to 25+ countries. Key segments include injectables (10-12% growth guidance), tablets (7-8% growth), Pune IV plant (targeting INR 60-65 crore revenue with 17-18% EBITDA margins), and a 45% stake in a European nutraceutical JV. Growth hinges on Pune IV plant scaling to 70% utilization by Q4 FY27 (from 20-23% currently), with sequential revenue improvement from Q1 FY27 as 18 products pipeline commercialize. Over 2-3 years, the base business will stabilize at 15.5-16.5% EBITDA margins while Pune IV becomes a margin-accruing engine. Key execution risk: geopolitical disruptions to 40-45% of export revenue from Middle East/CIS markets.

Why is Sanjiv.Parant. stock rising?

• Export revenues expected to recover in Q1 FY'27 (April-June 2026) after March disruption
• Pune IV facility revenue expected to improve sequentially in Q1 FY'27 and beyond as more products commercialize
• Base business revenue target of INR 80-85 crore for FY'27; IV plant revenue target of INR 60-65 crore
• Tablet and capsule portfolio expected to substantially increase due to new dossier approvals in coming year
• Pune facility utilization expected to reach 70% by Q4 FY'27, with gradual quarterly ramp-up

Research report

companyname: Sanjivani Paranteral Limited ticker: 531569 sector: Pharmaceuticals / Injectables & Oral Solids Manufacturing Sanjivani Paranteral Limited is a WHO GMP-certified pharmaceutical manufacturer with over 25 years of operating experience. The company specializes in sterile injectables, oral solid dosage forms, and nutraceuticals, with a primary focus on essential and life-saving therapies. It operates manufacturing facilities in Navi Mumbai and Dehradun, supported by in-house R&D. The c...

Catalysts

capex, margin expansion

Growth guidance

FY27 revenue guided at INR 80-85 crores for base business and INR 60-65 crores for Pune IV plant driven by export normalization and Pune plant scale-up